This excerpt taken from the PGNX 8-K filed May 16, 2005.
PROGENICS PHARMACEUTICALS ADDED TO NASDAQ
Tarrytown, NY May 16, 2005 Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that it was selected for addition to the NASDAQ Biotechnology Index(R) effective Monday, May 23, 2005. All securities in the Index are listed on the NASDAQ National Market and must meet certain eligibility criteria, including market value, average daily share volume and seasoning as a public company.
We are pleased to be included in the NASDAQ Biotechnology Index, said Paul J. Maddon, M.D., Ph.D., Progenics Chief Executive Officer and Chief Science Officer. Progenics has met important milestones this year with positive clinical trial results for our investigational drug methylnaltrexone (MNTX) and with our clinical development programs in general. We believe our selection for this index will enhance our visibility with the investment community as we continue to progress on our corporate and financial goals.
Launched in 1993, the NASDAQ Biotechnology Index includes securities that are classified according to the FTSE Global Classification System(TM) as biotechnology or pharmaceutical, and is ranked on a semi-annual basis in May and November. The NASDAQ Biotechnology Index is the basis for the iShares Nasdaq Biotechnology Index(SM) Fund (Amex: IBB). For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.NASDAQ.com.